Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Subjects Aged 40 Years and Older
NCT06088745 is registered in ClinicalTrials.gov with Beijing Luzhu Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Subjects Aged 40 Years and Older
- Lead sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 28, 2023
- Completion date
- December 31, 2026
- Enrollment
- 4 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.